Glaukos Corp. today announced it has completed enrollment for a 510(k) study of an implantable drainage device designed to lower eye pressure in glaucoma patients.
The study enrolled 110 adult patients with primary open-angle glaucoma who failed previous medical and surgical treatment.
Results from the study will support a future FDA marketing submission. The device, dubbed Preserflo MicroShunt, is currently approved and commercially available in Canada and Australia.
Shares in Glaukos were down 1.3% to $151.63 apiece and an $8.9 billion market cap (NYSE: GKOS).